Details for New Drug Application (NDA): 206910
✉ Email this page to a colleague
NDA 206910 describes JADENU, which is a drug marketed by Novartis Pharms Corp and Novartis and is included in two NDAs. It is available from one supplier. There is one patent protecting this drug and three Paragraph IV challenges. Additional details are available on the JADENU profile page.
The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 206910
| Tradename: | JADENU |
| Applicant: | Novartis Pharms Corp |
| Ingredient: | deferasirox |
| Patents: | 1 |
Suppliers and Packaging for NDA: 206910
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| JADENU | deferasirox | TABLET;ORAL | 206910 | NDA | Novartis Pharmaceuticals Corporation | 0078-0654 | 0078-0654-15 | 30 TABLET, FILM COATED in 1 BOTTLE (0078-0654-15) |
| JADENU | deferasirox | TABLET;ORAL | 206910 | NDA | Novartis Pharmaceuticals Corporation | 0078-0655 | 0078-0655-15 | 30 TABLET, FILM COATED in 1 BOTTLE (0078-0655-15) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 90MG | ||||
| Approval Date: | Mar 30, 2015 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Nov 21, 2034 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 180MG | ||||
| Approval Date: | Mar 30, 2015 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Nov 21, 2034 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 360MG | ||||
| Approval Date: | Mar 30, 2015 | TE: | AB | RLD: | Yes | ||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Nov 21, 2034 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Expired US Patents for NDA 206910
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | ⤷ Subscribe | ⤷ Subscribe |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | ⤷ Subscribe | ⤷ Subscribe |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | ⤷ Subscribe | ⤷ Subscribe |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | ⤷ Subscribe | ⤷ Subscribe |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | ⤷ Subscribe | ⤷ Subscribe |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
